Balchem Corp. Q1 2003 Financial Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 2003. Balchem Corporation develops, manufactures, and markets specialty performance ingredients for the food, feed, and medical sterilization industries. The company operates through three segments: Specialty Products, Encapsulated/Nutritional Products, and Unencapsulated Feed Supplements.
Key Financial Metrics
| Metric | Q1 2003 | Q1 2002 |
|---|---|---|
| Net Sales | $14,816 | $14,389 |
| Gross Profit | $5,651 | $5,294 |
| Gross Margin | 38.1% | 36.8% |
| Operating Income | $2,757 | $2,426 |
| Net Earnings | $1,683 | $1,438 |
| Diluted EPS | $0.34 | $0.29 |
| Operating Cash Flow | $1,642 | $2,676 |
| Working Capital | $12,387 | $10,884 (Dec 2002) |
| Total Debt (Current + Long-term) | $10,887 | $11,323 (Dec 2002) |
Note: All dollar amounts in thousands, except per share data.
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 2.9% year-over-year, driven by an 11.1% increase in the Specialty Products segment (higher volumes of ethylene and propylene oxide products) and a 2.0% increase in Unencapsulated Feed Supplements.
- Segment Performance: The Encapsulated/Nutritional Products segment saw a 3.5% sales decline due to a 13.5% volume drop in the domestic food market, partially offset by international growth. However, this segment turned a loss of $198k in Q1 2002 into a profit of $159k in Q1 2003.
- Profitability: Gross margin improved to 38.1% from 36.8%, aided by increased production volumes in specialty and feed supplement lines. Operating expenses remained flat as a percentage of sales (19.5% vs 19.9%).
- Interest Expense: Decreased by $31k to $74k due to lower average outstanding borrowings and reduced interest rates.
- Cash Flow: Operating cash flow decreased significantly to $1.642M from $2.676M, primarily due to decreases in accounts payable and accrued expenses, and an increase in accounts receivable.
Outlook, Risks, and Contingencies
- Capital Expenditures: Projected to be approximately $2.4M for calendar year 2003. Recent spending includes facility expansion in Verona, Missouri, and a new office lease.
- Debt Covenants: The company is in compliance with all restrictive covenants of its Loan Agreement. A $3.0M revolving credit facility expires May 31, 2003, and management intends to seek renewal.
- Contingent Consideration: Related to the 2001 acquisition of DCV, Inc., the company received a $30k reimbursement in Q1 2003. It may still be liable for up to $2.0M in future contingent payments based on gross margin performance over the remaining two years of the agreement.
- Stock Repurchase: The company has repurchased 343,316 shares under its program, with 108,251 shares held in treasury as of March 31, 2003.
- Market Risk: The company has variable-rate debt (LIBOR + 1.25%). A 100 basis point increase in rates would increase annual interest expense by approximately $109k. There is no material exposure to foreign currency or commodity price risk.
Investor Verification Checklist
- Verify the renewal status of the $3.0M revolving credit facility expiring May 31, 2003.
- Monitor the performance of the Encapsulated/Nutritional Products segment to ensure the domestic food market volume decline does not persist.
- Track the potential $2.0M contingent payment obligation related to the DCV acquisition.
- Review the impact of working capital changes (specifically accounts payable and receivable) on future operating cash flow.
- Confirm the company's ability to maintain financial ratios required by the term loan agreement.